Selectivity and mechanism of action of a growth factor receptor-bound protein 2 Src homology 2 domain binding antagonist

Journal of Medicinal Chemistry

Volumn 51, Issue 23, 2008, Pages 7459-7468

  Giubellino, Alessio ^a   Shi, Zhen Dan ^b   Miller Jenkins, Lisa M ^a   Worthy, Karen M ^c   Bindu, Lakshman K ^c   Athauda, Gagani ^a   Peruzzi, Benedetta ^a   Fisher, Robert J ^c   Appella, Ettore ^a   Burke Jr , Terrence R ^b   Bottaro, Donald P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [2 [ 1 [2 CARBAMOYL 1 [3 [5 [6 [5 (2 OXOHEXAHYDROTHIENO[3,4 D]IMIDAZOL 6 YL)PENTANOYLAMINO]HEXANOYLOXY]NAPHTHALEN 1 YL]PROPYLCARBAMOYL]CYCLOHEXYLCARBAMOYL] 2 (OXALYLAMINO)ETHYL]PHENYLMALONIC ACID; FOCAL ADHESION KINASE 1; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2 SRC HOMOLOGY 2 DOMAIN BINDING ANTAGONIST; P21 ACTIVATED KINASE 1; PROTEIN SH2; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BIOTINYLATION; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MASS SPECTROMETRY; METASTASIS; MOLECULAR MECHANICS; NONHUMAN; PROTEIN DOMAIN; PROTEIN IMMOBILIZATION; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE;

BINDING SITES; BIOTIN; CELL LINE, TUMOR; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GRB2 ADAPTOR PROTEIN; HUMANS; MOLECULAR STRUCTURE; SRC HOMOLOGY DOMAINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57349182187     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800523u     Document Type: Article

References (28)

1. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature 2001, 411, 355-365.
2. Lowenstein, E. J.; Daly, R. J.; Batzer, A. G.; Li, W.; Margolis, B.; Lammers, R.; Ullrich, A.; Skolnik, E. Y.; Bar-Sagi, D.; Schlessinger, J. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992, 70, 431-442.
3. Songyang, Z.; Shoelson, S. E.; McGlade, J.; Olivier, P.; Pawson, T.; Bustelo, X. R.; Barbacid, M.; Sabe, H.; Hanafusa, H.; Yi, T. Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol. Cell. Biol. 1994, 14, 2777-2785.
4. Tari, A. M.; Lopez-Berestein, G. GRB2: A pivotal protein in signal transduction. Semin. Oncol. 2001, 28, 142-147.
5. Kumar, R.; Gururaj, A. E.; Barnes, C. J. p21-activated kinases in cancer. Nat. Rev. Cancer 2006, 6, 459-471.
6. Schlaepfer, D. D.; Hanks, S. K.; Hunter, T.; Van der Geer, P. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature 1994, 372, 786-791.
7. Mitra, S. K.; Mikolon, D.; Molina, J. E.; Hsia, D. A.; Hanson, D. A.; Chi, A.; Lim, S. T.; Bernard-Trifilo, J. A.; Ilic, D.; Stupack, D. G.; Cheresh, D. A.; Schlaepfer, D. D. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 2006, 25, 5969-5984.
8. McLean, G. W.; Carragher, N. O.; Avizienyte, E.; Evans, J.; Brunton, V. G.; Frame, M. C. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat. Rev. Cancer 2005, 5, 505-515.
9. Dharmawardana, P. G.; Peruzzi, B.; Giubellino, A.; Burke, J.; Bottaro, D. P. Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anti-Cancer Drugs 2006, 17, 13-20.
10. Burke, T. R. Development of Grb2 SH2 domain signaling antagonists: a potential new class of antiproliferative agents. Int. J. Pept. Res. Ther. 2006, 12, 33-48.
11. Atabey, N.; Gao, Y.; Yao, Z. J.; Breckenridge, D.; Soon, L.; Soriano, J. V.; Burke, T. R.; Bottaro, D. P. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J. Biol. Chem. 2001, 276, 14308-14314.
12. Soriano, J. V.; Liu, N.; Gao, Y.; Yao, Z. Y.; Ishibashi, T.; Underhill, C.; Burke, T. R.; Bottaro, D. P. Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain binding antagonists. Mol. Cancer Ther. 2004, 3, 1289-1299.
13. Giubellino, A.; Gao, Y.; Lee, S.; Lee, M. J.; Vasselli, J. R.; Medepalli, S.; Trepel, J. B.; Burke, T. R.; Bottaro, D. P. Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res. 2007, 67, 6012-6016.
14. Shi, Z. D.; Liu, H.; Zhang, M.; Worthy, K. M.; Bindu, L.; Yang, D.; Fisher, R. J.; Burke, T. R. Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity. Bioorg. Med. Chem. 2005, 13, 4200-4208.
15. Sasaki, H.; Irie, R.; Hamada, T.; Suzuki, K.; Katsuki, T. Rational design of Mn-salen catalyst (2): highly enantioselective epoxidation of conjugated cis-olefins. Tetrahedron 1994, 50, 11827-11838.
16. Cabri, W.; Candiani, I.; Bedeschi, A.; Santi, R. 1,10-Phenanthroline derivatives: a new ligand class in the Heck reaction. Mechanistic aspects. J. Org. Chem. 1993, 58, 7421-7426.
17. Gao, Y.; Burke, T. R. Stereoselective preparation of L-4- (2′-malonyl)phenylalanine suitably protected for Fmoc-based synthesis of potent signal transduction inhibitory ligands. Synlett 2000, 134-136.
18. Mikol, V.; Baumann, G.; Zurini, M. G. M.; Hommel, U. Crystal structure of the SH2 domain from the adaptor protein SHC: a model for peptide binding based on X-ray and NMR data. J. Mol. Biol. 1995, 254, 86-95.
19. Oishi, S.; Karki, R. G.; Shi, Z. D.; Worthy, K. M.; Bindu, L.; Chertov, O.; Esposito, D.; Frank, P.; Gillette, W. K.; Maderia, M.; Hartley, J.; Nicklaus, M. C.; Barchi, J.; Fisher, R. J.; Burke, T. R. Evaluation of macrocyclic Grb2 SH2 domain-binding peptide mimetics prepared by ring-closing metathesis of C-terminal allylglycines with an N-terminal beta-vinyl-substituted phosphotyrosyl mimetic. Bioorg. Med. Chem. 2005, 13, 2431-2438.
20. Puto, L. A.; Pestonjamasp, K.; King, C. C.; Bokoch, G. M. p21-activated kinase 1 (PAK1) interacts with the Grb2 adapter protein to couple to growth factor signaling. J. Biol. Chem. 2003, 278, 9388-9393.
21. Singh, R. R.; Song, C.; Yang, Z.; Kumar, R. Nuclear localization and chromatin targets of p21-activated kinase 1. J. Biol. Chem. 2005, 280, 18130-18137.
22. O'Sullivan, G. C.; Tangney, M.; Casey, G.; Ambrose, M.; Houston, A.; Barry, O. P. Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma. Int. J. Cancer 2007, 121, 1930-1940.
23. Rayala, S. K.; Kumar, R. Sliding p21-activated kinase 1 to nucleus impacts tamoxifen sensitivity. Biomed. Pharmacother. 2007, 61, 408-411.
24. Machida, K.; Mayer, B. J. The SH2 domain: versatile signaling module and pharmaceutical target. Biochim. Biophys. Actaica et Biophysica Acta, Proteins Proteomics 2005, 1747, 1-25.
25. Songyang, Z.; Shoelson, S. E.; Chaudhuri, M.; Gish, G.; Pawson, T.; Haser, W. G.; King, F.; Roberts, T.; Ratnofsky, S.; Lechleider, R. J.; Neel, B. G.; Birge, R. B.; Fajardo, J. E.; Chou, M. M.; Hanafusa, H.; Schaffhausen, B.; Cantley, L. C. SH2 domains recognize specific phosphopeptide sequences. Cell 1993, 72, 767-778.
26. Gao, Y.; Luo, J.; Yao, Z.-J.; Guo, R.; Zou, H.; Kelley, J.; Voigt, J. H.; Yang, D.; Burke, T. R. Inhibition of Grb2 SH2 domain binding by non-phosphate- containing ligands 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. J. Med. Chem. 2000, 43, 911-920.
27. Gay, B.; Suarez, S.; Caravatti, G.; Furet, P.; Meyer, T.; Schoepfer, J. Selective Grb2 SH2 inhibitors as anti-Ras therapy. Int. J. Cancer 1999, 83, 235-241.
28. Oishi, S.; Shi, Z. D.; Worthy, K. M.; Bindu, L. K.; Fisher, R. J.; Burke, T. R. Ring-closing metathesis of C-terminal allylglycine residues with an N-terminal beta-vinyl-substituted phosphotyrosyl mimetic as an approach to novel Grb2 SH2 domain-binding macrocyles. ChemBioChem 2005, 6, 668-674.